IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Exercise Dose and Nonalcoholic Fatty Liver Disease (ED)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention |
|---|---|
| Non-alcoholic Fatty Liver Disease (NAFLD) | Behavioral: exercise |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Exercise Dose and Nonalcoholic Fatty Liver Disease |
- The effect of aerobic exercise on: Intrahepatic fat content [ Time Frame: 3 years ]
- VLDL-triglyceride (TG) and VLDL-Apolipoprotein B (apoB) kinetics [ Time Frame: 3 years ]
- Insulin action in liver (suppression of glucose production), muscle (stimulation of glucose uptake), and adipose tissue (suppression of lipolysis). [ Time Frame: 3 years ]
- Plasma markers of inflammation [ Time Frame: 3 years ]
- Potential cellular mechanisms responsible for changes in insulin action and inflammation [ Time Frame: 3 years ]
| Enrollment: | 33 |
| Study Start Date: | May 2006 |
| Study Completion Date: | April 2011 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: control
Subjects will serve as controls, continuing current diet and activity levels. Subjects will get monthly weights by the investigator at the research center.
|
|
|
Experimental: Exercise
For 16 weeks subjects will exercise from 30-60 minutes five times a week.
|
Behavioral: exercise
For 16 weeks subjects will exercise from 30-60 minutes five times a week.
Other Name: walking
|
Detailed Description:
Non-alcoholic fatty liver disease (NAFLD) affects about 33% of adults in the United States. The prevalence of NAFLD is four to five times higher in obese than lean persons and is associated with insulin resistance and the metabolic syndrome. Decreasing calorie intake and increasing physical activity has been recommended as primary therapy for NAFLD, but the independent effect of aerobic exercise is unknown. The current exercise guidelines for disease prevention and weight management range from 150 min/wk, recommended by the Centers for Disease Control and the American College of Sports Medicine, to 300 min/wk, recommended by the Institute of Medicine. However, it is not known whether aerobic exercise alone can improve NAFLD, and which recommended dose of exercise might have the most beneficial effects. The purpose of this proposal is to determine the effect of moderate intensity endurance exercise on: 1) hepatic fat content; 2) hepatic lipoprotein kinetics; and 3) plasma inflammatory markers. We hypothesize that aerobic exercise will decrease hepatic fat content, improve VLDL kinetics, and decrease inflammation in a dose-dependent fashion. The results from this study will help determine exercise guidelines for obese patients with NAFLD, and lay the groundwork for future studies evaluating the effects of exercise on metabolic diseases associated with obesity.
This proposal involves conducting a randomized controlled trial that will randomize obese subjects with NAFLD (> 10% hepatic fat content) to one of two groups: Group 1 (Control, no exercise) and Group 2 (Moderate Intensity Aerobic Exercise- 150 min/wk to 300 min/wk of supervised exercise performed at 45-55% of O2 max).
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 18-65 with Nonalcoholic Fatty Liver Disease as determined by MRS
Exclusion Criteria:
-
Medical History
- Diabetes
- Heart Disease
- Asthma/Lung disease
- Injury that prevents exercise
-
Social history
- Drinking
- More than one drink per day
- Binge drinking on the weekends (more than 3 or 4 drinks per weekend day)
- Smoking
- It's OK if they were a previous smoker, but they need to have quit more than 6 months ago
-
Exercise
- They must exercise less than one hour per week
- Medications: must be on stable regimen of ANY medication for at least 3 months
-
Beta-Blockers
- Lipid/cholesterol lowering medications:
- Oral hypoglycemics (anti-diabetes medications - some like metformin are indicated for pre-diabetes)
- Hormone replacement therapy
- If the woman is pre-menopausal, it is OK if she is on birth control as long as she has been on it over 3 months
-
Weight history
- Weight <300 lbs
- BMI 30 to 45
- Weight stable - <10lbs weight loss or gain in the last 3 months
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00771108
| United States, Missouri | |
| Washington University School of Medicine | |
| St. Louis, Missouri, United States, 63110 | |
| Principal Investigator: | Samuel Klein, MD | Washington University School of Medicine |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Washington University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00771108 History of Changes |
| Other Study ID Numbers: |
06-0039 #5P30 DK052574 (NIH/DDRCC) R01 DK37948 (NIH/NIDDK) |
| Study First Received: | October 9, 2008 |
| Last Updated: | September 2, 2011 |
Keywords provided by Washington University School of Medicine:
|
NAFLD Obesity Metabolic Syndrome Nonalcoholic Fatty Liver Disease |
Additional relevant MeSH terms:
|
Liver Diseases Fatty Liver Non-alcoholic Fatty Liver Disease Digestive System Diseases |
ClinicalTrials.gov processed this record on June 23, 2017